v3.24.2.u1
CONSOLIDATED STATEMENTS OF (DEFICIT) EQUITY - USD ($)
$ in Thousands
Series A Convertible Preferred Stock
Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Other Comprehensive Income
Accumulated Deficit
Total
Balance Beginning at Dec. 31, 2022 $ 4,043 $ 50 $ 542,428     $ (430,521) $ 116,000
Balance Beginning (in shares) at Dec. 31, 2022 4,300 49,642,767   7,307      
Increase (Decrease) in Stockholders' Equity (Deficit)              
Stock-based compensation expense     3,741       3,741
Net issuance of common stock in connection with the vesting of restricted stock (in shares)   22,350          
Unrealized gain (loss) on short-term investments         $ 74   74
Net Income (Loss)           (34,730) (34,730)
Balance Ending at Mar. 31, 2023 $ 4,043 $ 50 546,169   74 (465,251) 85,085
Balance Ending (in shares) at Mar. 31, 2023 4,300 49,665,117   7,307      
Increase (Decrease) in Stockholders' Equity (Deficit)              
Stock-based compensation expense     3,891       3,891
Net issuance of common stock in connection with the vesting of restricted stock (in shares)   11,625          
Exercise of stock options     485       485
Exercise of stock options (in shares)   72,440          
Conversion of convertible preferred stock into common $ (4,043) $ 1 4,042        
Conversion of convertible preferred stock into common stock (in shares) (4,300) 860,000          
Unrealized gain (loss) on short-term investments         (188)   (188)
Net Income (Loss)           (31,934) (31,934)
Balance Ending at Jun. 30, 2023   $ 51 554,587   (114) (497,185) 57,339
Balance Ending (in shares) at Jun. 30, 2023   50,609,182   7,307      
Balance Beginning at Dec. 31, 2023   $ 55 588,656   (20) (571,926) 16,765
Balance Beginning (in shares) at Dec. 31, 2023   54,578,121   7,307      
Increase (Decrease) in Stockholders' Equity (Deficit)              
Stock-based compensation expense     5,193       5,193
Net issuance of common stock in connection with the vesting of restricted stock (in shares)   295,256          
Exercise of stock options     257       257
Exercise of stock options (in shares)   57,665          
Unrealized gain (loss) on short-term investments         20   20
Net Income (Loss)           (38,669) (38,669)
Balance Ending at Mar. 31, 2024   $ 55 594,106     (610,595) (16,434)
Balance Ending (in shares) at Mar. 31, 2024   54,931,042   7,307      
Balance Beginning at Dec. 31, 2023   $ 55 588,656   $ (20) (571,926) 16,765
Balance Beginning (in shares) at Dec. 31, 2023   54,578,121   7,307      
Increase (Decrease) in Stockholders' Equity (Deficit)              
Net Income (Loss)             (74,500)
Balance Ending at Jun. 30, 2024   $ 55 599,023     (646,423) (47,345)
Balance Ending (in shares) at Jun. 30, 2024   54,963,919   7,307      
Balance Beginning at Mar. 31, 2024   $ 55 594,106     (610,595) (16,434)
Balance Beginning (in shares) at Mar. 31, 2024   54,931,042   7,307      
Increase (Decrease) in Stockholders' Equity (Deficit)              
Stock-based compensation expense     4,917       4,917
Net issuance of common stock in connection with the vesting of restricted stock (in shares)   32,877          
Net Income (Loss)           (35,828) (35,828)
Balance Ending at Jun. 30, 2024   $ 55 $ 599,023     $ (646,423) $ (47,345)
Balance Ending (in shares) at Jun. 30, 2024   54,963,919   7,307